|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating costs and expenses: | |||||
| Research, development and clinical studies | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Total operating costs and expenses | |||||
| Operating income (loss) | |||||
| Financial (expenses) income, net | |||||
| Total income (loss) before income taxes | |||||
| Income tax | |||||
| Net income (loss) | |||||
| Basic net income (loss) per ordinary share (in usd per share) | |||||
| Diluted net income (loss) per ordinary share (in usd per share) | |||||
| Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | |||||
| Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | |||||
Loading...
